Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adding hepatic arterial infusion chemotherapy (HAIC) to camrelizumab and rivoceranib significantly improves survival for advanced liver cancer with portal vein tumor thrombosis (PVTT). This triple therapy offers better outcomes and is well-tolerated compared to dual therapy alone.
Area Of Science
- Hepatobiliary Oncology
- Hepatocellular Carcinoma (HCC) Research
- Advanced Cancer Therapeutics
Background
- Portal vein tumor thrombosis (PVTT) indicates advanced hepatocellular carcinoma (HCC) with a poor prognosis.
- Sorafenib monotherapy shows limited efficacy for HCC with PVTT.
- Hepatic arterial infusion chemotherapy (HAIC) and dual camrelizumab/rivoceranib therapy offer improved survival in advanced HCC.
Purpose Of The Study
- To investigate the safety and efficacy of combining HAIC with camrelizumab and rivoceranib for HCC patients with PVTT.
- To compare the triple therapy (HAIC + camrelizumab + rivoceranib) against dual therapy (camrelizumab + rivoceranib) as first-line treatment.
- To evaluate survival prognosis, tumor response, and adverse reactions of the two treatment regimens.
Main Methods
- Retrospective review of 411 HCC patients with PVTT receiving first-line triple or dual therapy at four Chinese centers (Jan 2020-Dec 2021).
- Propensity score matching (PSM) applied to balance intergroup differences, resulting in 83 matched pairs.
- Comparison of overall survival (mOS), progression-free survival (mPFS), objective response rate (ORR), and disease control rate (DCR).
Main Results
- The triple therapy group (HAICCR) showed significantly longer mOS (19.6 vs. 11.5 months) and mPFS (10.0 vs. 5.6 months) than the dual therapy group (CR) (p<0.0001).
- HAICCR also demonstrated higher ORR (55.5% vs. 42.0%) and DCR (89.0% vs. 79.0%).
- Adverse events like hypertension and hand-foot syndrome were common but not significantly different between groups.
Conclusions
- The triple regimen of HAIC, camrelizumab, and rivoceranib significantly prolongs survival in advanced HCC patients with PVTT.
- This combination therapy is well-tolerated and shows superior efficacy compared to dual camrelizumab/rivoceranib therapy.
- The triple regimen represents a promising therapeutic option for HCC with PVTT.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...